摘要
目的探讨总前列腺相关抗原(TPSA)、游离前列腺相关抗原(FPSA)、FPSA/TPSA比值和铁蛋白单独检测和联合检测对于前列腺癌的诊断价值。方法检测94例前列腺癌组患者、103例前列腺增生组患者和104名对照组血清TPSA、FPSA和Ferr的含量。结果 TPSA、FPSA、FPSA/TPSA和Ferr中,作为单独区分前列腺增生(BPH)和前列腺癌(PCA)最好指标为FPSA/TPSA,诊断灵敏性和特异性分别为82.3%和59.8%;最差的为FPSA,诊断灵敏性和特异性分别为69.3%和52.1%。单独指标区分诊断能力难以同时满足临床灵敏性和特异性的需要;利用二元Logistic回归分析FPSA、TPSA、FPSA/TPSA和Ferr的联合检测,灵敏性和特异性分别为72.6%和79.8%。结论 TPSA、FPSA、FPSA/TPSA和Ferr的联合检测可提高对BPH和PCA的诊断价值,可作为辅助诊断方法应用于临床。
Objective To explore the clinical value of determination of the total prostate-associated antigen (TPSA),free prostate-associated antigen (FPSA),FPSA/TPSA ratio and ferritin alone and jointly for prostate cancer.Methods The concentration of TPSA,FPSA,ferritin and FPSA / TPSA were detected in 94 prostate cancer patients,103 benign prostatic hyperplasia patients and 104 healthy controls.Results When the TPSA,FPSA,FPSA/TPSA and Ferr were detected alone to differentiate the benign prostatic hyperplasia and prostate cancer,the best diagnostic indicator was FPSA / TPSA.The diagnostic sensitivity and specificity were 82.3%and 59.8%,respectively.The worst was FPSA,the diagnostic sensitivity and specificity were 69.3% and 52.1%,respectively.When the indicators were used alone for the distinction between PCA and BPH,the diagnostic value cannot meet the clinical need.Binary logistic regression analysis was used for the FPSA,TPSA,FPSA/ TPSA andferritin joint diagnosis.The diagnostic value was greater than that by any indicator alone,the diagnostic sensitivity and specificity were 72.6% and 79.8%,respectively.Conclusion The joint detection of TPSA,FPSA,FPSA/TPSA and Ferritin could improve the diagnostic value,and can be served as an aided diagnosis method for clinical application.
出处
《标记免疫分析与临床》
CAS
2014年第2期160-162,共3页
Labeled Immunoassays and Clinical Medicine
关键词
前列腺癌
前列腺增生
前列腺相关抗原
铁蛋白
联合检测
Prostate cancer
Benign prostatic hyperplasia
Prostate-associated antigen
Ferritin
Combined detection